Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Maxcyte, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Maxcyte, Inc. is a small-cap company with a market capitalization of $134M. It ranks number 9 by market capitalization among the 15 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast. Its P/B Ratio of 0.85x is the lowest of the 10 peers that report one. Its Current Ratio of 12.26x is the highest of the 16 peers that report one.
For MXCT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 31.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 44.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MXCT included.
Follow MXCT free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
| Metric | MXCT | Rank |
|---|---|---|
| Market Cap | $134M | 9/15 |
| P/B Ratio | 0.85x | 10/10 |
| EPS | $-0.38 | – |
| Book Value/Share | $1.54 | – |
| Revenue/Share | $0.30 | – |
| FCF/Share | $-0.23 | – |
| Metric | MXCT | Rank |
|---|---|---|
| ROE | -22.4% | 7/9 |
| ROA | -19.3% | 7/11 |
| ROIC | -23.9% | 11/11 |
| Gross Margin | 79.2% | 2/7 |
| Operating Margin | -134.6% | 8/13 |
| Net Margin | -114.8% | 6/10 |
| EBT Margin | -114.8% | 7/13 |
| Metric | MXCT | Rank |
|---|---|---|
| Current Ratio | 12.26x | 1/16 |
| Quick Ratio | 11.47x | 1/6 |
| D/E Ratio | 0.16x | 10/11 |
| Financial Leverage | 1.16x | 9/10 |
| Interest Coverage | -818.0x | 12/13 |
| Working Capital | $111M | 4/15 |
| Metric | MXCT | Rank |
|---|---|---|
| Operating Cash Flow | -$23M | 14/15 |
| Free Cash Flow | -$24M | 6/7 |
| Capital Spending | -$670K | 3/7 |
| FCF/Sales | -76.1% | 6/8 |
| CapEx/Sales | 2.1% | 5/8 |
| Metric | MXCT | Rank |
|---|---|---|
| Asset Turnover | 0.17x | 7/8 |
| Receivables Turnover | 7.9x | 2/7 |
| Inventory Turnover | 0.8x | – |
| Fixed Assets Turnover | 2.1x | 8/9 |
| Days Sales Outstanding | 46 days | 6/7 |
| Days Inventory | 441 days | – |
| Payables Period | 98 days | 4/6 |
| Cash Conversion Cycle | 389 days | – |
| Metric | MXCT | Rank |
|---|---|---|
| Total Revenue | $31M | 6/8 |
| Operating Income | -$42M | 13/15 |
| Net Income | -$36M | 9/12 |
| R&D Expense | $17M | 4/7 |
| SG&A Expense | $47M | 6/12 |
| Cost of Goods Sold | $6M | 4/8 |
| Metric | MXCT | Rank |
|---|---|---|
| Shares Outstanding | 103M | – |
| Total Current Assets | $121M | 65.7% of assets |
| Cash & Short-term Investments | $15M | 8.1% of assets |
| Accounts Receivable | $4M | 2.1% of assets |
| Inventory | $8M | 4.2% of assets |
| Total Liabilities | $26M | 14.0% of assets |
| Short-term Debt | $8M | 4.4% of assets |
Companies classified under the same SEC industry code as Maxcyte, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| MXCT Maxcyte, Inc. | ▲ | $134M |
| IQV Iqvia Holdings Inc. | ▼ | $45.37B |
| INCY Incyte Corp | ▶ | $22.20B |
| MEDP Medpace Holdings, Inc. | ▼ | $17.26B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.33B |
| ICLR Icon Plc | ▶ | $13.13B |
| ABSI Absci Corp | ▲ | $1.42B |
| OABI Omniab, Inc. | ▲ | $667M |
| NRC Nrc Health | ▲ | $446M |
| ONMD Onemednet Corp | ▲ | $28M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | $5M |
| BUDZ Weed, Inc. | ▲ | $3M |
| ISPC Ispecimen Inc. | ▼ | $3M |
| FOXO Foxo Technologies Inc. | ▼ | $180K |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell ...
MaxCyte Inc (NASDAQ:MXCT) is set to release its Q2 2025 earnings on August 6, 2025. The consensus estimate for Q2 2025 revenue is $9.57 million, and the earnings are expected to come in at -$0.10 per ...
MaxCyte, Inc. provided preliminary unaudited revenue guidance for the third quarter ended September 30, 2026 and updated revenue guidance for the second half of the year 2026. For the quarter, ...
Our AI ranks Maxcyte, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For MXCT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 31.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 44.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Maxcyte, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
16 issuers in our coverage, MXCT included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.